Patient Financing: The Lender You're Leaving on the Table

Americans spent $189 billion on dental care in 2024, up 3.6% after inflation, and the largest single slice of that bill didn't come from an insurance carrier. It came straight out of patients' pockets, according to the ADA Health Policy Institute, which means the biggest payer in your practice has no fee schedule, no EOB, no contract, and no credentialing packet. Most owners still treat that payer as if the wallet is empty.

Here is our thesis, and plenty of owners will fight it: the merchant fee you pay a third-party patient lender is the cheapest production you will ever buy, and a practice that refuses to eat 9% or 12% on an accepted case while cheerfully absorbing a 30%-plus contractual write-off on every single procedure is making a choice it cannot defend with arithmetic. A financing fee is the only discount in dentistry you pay only when the answer is yes.

The Biggest Payer in Dentistry Never Sends an EOB

Practice owners build entire administrative departments around insurance. Credentialing, fee negotiations, claim scrubbing, appeals, attachment uploads, aging reports sorted by carrier. That infrastructure exists to chase the second-largest source of dental revenue. Out-of-pocket spending is the largest, per the ADA's market data, and the typical practice manages it with a countertop card terminal and a treatment coordinator who was never trained on anything except "do you want to put that on a card today?"

That asymmetry is the whole problem. You have a full-time person fighting a carrier over a $340 crown downgrade while a $6,800 quadrant-of-perio-plus-implant case walks out the door because nobody offered a payment structure. One of those is a rounding error. The other is your year.

The labor math makes it worse. The Bureau of Labor Statistics puts the median dentist wage at $176,110 as of May 2025, across 161,400 dentist jobs, with roughly 4,800 openings projected annually through 2035. You are not hiring your way to more production. There is no queue of associates waiting to fill your third operatory at a price that works. The only real growth lever most practices have left is converting more of the treatment they already diagnosed in the chairs they already own.

Insured Doesn't Mean Able to Pay

The single most expensive assumption in a dental front office is that a patient with a card in the system is a patient who can pay. The data says otherwise, loudly.

KFF found that cost kept insured adults out of the operatory at rates that should embarrass the entire benefits industry: 39% of adults with Medicaid, 37% with Marketplace coverage, 26% with Medicare, and 25% with employer-sponsored insurance delayed or went without dental care because of cost in the past year. At least one in four insured adults. Broaden that to all adults and roughly 27% delay or forgo needed care over cost.

The Synchrony and CareCredit Dental Lifetime of Care Study sharpens it further: 58% of adults surveyed consider dental care unaffordable, 92% would consider delaying general care over cost, and 83% would delay even emergency care. Fifty-three percent of the people saying that already carry dental insurance.

Read that last number again. Half the patients in your hygiene schedule who have a benefit plan on file would still put off an emergency because of money. Your annual maximum is $1,500. Your comprehensive treatment plans are not.

What Most Owners Get Wrong: Pricing the Fee Against the Wrong Alternative

The mistake is specific, and it is made most often by the financially literate owner. Not the one who ignores numbers, the one who watches them closely. This owner looks at a 9.9% merchant fee on a 12-month promotional plan, compares it to a 2.6% credit card swipe, and concludes that patient financing is an expensive way to collect money. Then they instruct the team to "only offer it if the patient asks."

That comparison is wrong because the alternative to a financed case is almost never a swiped case. The alternative is no case. The patient who needs $6,800 of treatment and has $900 of room on a personal card does not become a cash payer when you decline to present financing. That patient becomes a recall reminder, then a lapsed chart, then somebody else's emergency.

Our view: the correct comparison is not financing fee versus card fee. It's financing fee versus 100% write-off. A 9.9% haircut on production you would otherwise never see is a 90.1% gain.

The second version of the mistake is sequencing. Financing gets introduced as a rescue after the patient has already said no, which means it arrives as a concession rather than a plan. By then the patient has mentally closed the file. Offering payment options at the moment of refusal converts far worse than building them into the presentation from the first sentence.

The third version is the moral one, and we hear it constantly: "I'm not putting my patients into debt." That instinct is decent and the outcome is not. Untreated disease is also a financial instrument. It compounds, it accrues interest in the form of endo, extraction, and implants, and the patient pays it either way.

$27,444 in Fees to Buy $163,800 in Production

Take a single-doctor general practice that presents 25 comprehensive cases a month at an average plan value of $4,200. That's $105,000 in monthly presented treatment.

At a 42% dollar-acceptance rate, the practice books $44,100 of it.

Now assume the practice rebuilds the financial conversation: pre-approval runs before the case presentation, monthly figures appear on the treatment plan itself, and every plan above $1,500 gets a structured payment option offered without being asked. Push dollar acceptance to 55% and the practice books $57,750 a month.

That's $13,650 a month in production that did not exist before.

It isn't free. Say 40% of accepted dollars now ride on third-party paper, which is $23,100 a month in financed volume.

At a 9.9% merchant fee (use your own rate sheet, promotional terms vary widely by plan length), that's $2,287 a month surrendered to the lender.

Annualized: $27,444 in fees against $163,800 in incremental production.

Net of the fee, that's $136,356 a year of new top line.

Because the fixed overhead is already paid, incremental cases drop through at a much better rate than blended margin. Assume 30% variable cost for lab, supplies, and clinical labor, and the contribution is $95,449.

Now set that next to the write-off you already accept without flinching. A practice with $600,000 in plan-covered production at a 32% average contractual adjustment gives away $192,000 a year, and it gives that away on every procedure, including the ones the patient would have accepted at full fee.

$27,444 paid only on yeses. $192,000 paid on everything. We'd take the fee every single time, and we'd stop pretending it's the expensive line item on the page.

In-House Paper Is a Loan You Underwrote by Accident

The common alternative is the in-house payment plan. Owner keeps the fee, patient pays $400 a month for six months, everybody feels good. What actually happened is that a dental practice became an unsecured consumer lender with no underwriting, no collections department, and no recourse.

The first two payments come in. Payment three is late. Payment four bounces. Now your office manager is spending Tuesday afternoons calling a patient about $400 instead of verifying benefits or filling tomorrow's holes. The collection cost alone eats the fee you saved, and the aging bucket over 90 days is where practice value goes to die.

Our call: run in-house plans only where you hold something back. Membership plans for hygiene and preventive care are a different animal and worth building, because the service is delivered monthly alongside the payment. Open-ended installment plans on completed restorative work are not. If the lab bill is paid and the crown is cemented, you have already delivered everything and retained nothing.

Where we'd spend the effort instead:

• A primary lender for prime credit, with promotional terms your team can quote from memory.
• A second-look lender for declines, so a "no" from the first application isn't the end of the conversation.
• A written internal policy on what does and does not get offered in-house, so the answer isn't invented case by case at the front desk.
• Soft-pull pre-approval run before the doctor walks in, not after the patient hesitates.

Where the Offer Actually Dies

Almost nobody loses these cases at the operatory. They lose them at the checkout counter, in the four seconds after a total is spoken aloud and before anyone says a number with the word "month" attached to it.

Listen to your own handoff. If the treatment coordinator's opening line is the full case total, the patient's nervous system has already answered before the options come out. Lead with the structure, then the total. "This plan is $312 a month over 24 months with no interest, and the full fee is $6,800." Same information, completely different conversation.

The other silent killer is the declined application with no next step. A patient who gets turned down and then gets handed a printed treatment plan and a "let us know" has been humiliated for free. A second-look program, or a staged sequence that starts with the urgent quadrant instead of the full mouth, keeps that patient in care.

Our view: case acceptance percentage is the wrong metric to run this on. Track unfinanced presented dollars, meaning treatment you diagnosed, presented, and never attached a payment structure to. That's the number that tells you what your system is losing, and almost no practice measures it.

Rewire the Money Conversation This Week

Pull your presented-versus-accepted dollars for the last 90 days and separate out every plan over $1,500 that closed with no payment option offered. Then set a rule starting Monday: nothing above $1,500 gets presented without a monthly figure printed on the plan, and pre-approval runs before the doctor enters the room, not after the patient balks. Add a second-look lender this week so a decline triggers a next step instead of a shrug. Re-pull the same report in 60 days and compare the unfinanced presented dollars, not the acceptance rate.

What we're watching next: whether promotional deferred-interest terms survive the current regulatory mood, because a change to how retroactive interest is disclosed would reprice this entire calculation. We'd also change our position on in-house plans if practices start showing us ledger data with over-90 collections above 90% on self-financed restorative balances. We haven't seen it yet. We'd like to be wrong.

The same math that decides whether a financing fee is worth paying decides whether a PPO contract is worth keeping: both are a question of what percentage you surrender and on which dollars. If you want to see what your write-offs are actually costing against a fee-for-service or financed alternative, run your own numbers through our PPO-exit calculator and compare the two side by side before your next contract renewal date.